Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $54.50

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average rating of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $54.50.

A number of research firms recently weighed in on OMCL. Piper Sandler restated an “overweight” rating and issued a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Wednesday, February 4th. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research report on Wednesday, January 7th. Weiss Ratings lowered Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. Finally, Wells Fargo & Company increased their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, January 5th.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.52% of the stock is currently owned by company insiders.

Institutional Trading of Omnicell

A number of large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 9.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after purchasing an additional 197,462 shares during the period. Wellington Management Group LLP lifted its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares during the period. Lazard Asset Management LLC lifted its stake in Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Omnicell by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after buying an additional 30,678 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Omnicell during the 3rd quarter worth approximately $25,625,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Up 1.7%

Shares of NASDAQ OMCL opened at $42.25 on Friday. The company has a 50 day simple moving average of $44.71 and a 200 day simple moving average of $38.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The firm has a market cap of $1.92 billion, a PE ratio of 1,056.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, research analysts forecast that Omnicell will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.